Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
2140
|
October 13, 2020
|
"Open label, double-masked trial"
|
|
0
|
2108
|
October 13, 2020
|
ANCOVA with randomized and nonrandomized groups
|
|
4
|
2024
|
September 30, 2020
|
Time since randomization and causality
|
|
2
|
1717
|
September 27, 2020
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
3779
|
September 22, 2020
|
Empirical Bayes for RCT Interpretarion
|
|
8
|
3894
|
August 11, 2020
|
Re-starting a Bayesian group sequential design trial after stopping it
|
|
4
|
2084
|
August 11, 2020
|
MERINO trial - adjusting for infection source
|
|
3
|
2526
|
August 3, 2020
|
Thoughts on 'representativeness' and 'generalizability'
|
|
6
|
2676
|
July 19, 2020
|
Interpretation of INTERACT-2 Study in Intracerebral Hemorrhage
|
|
3
|
2953
|
June 15, 2020
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
1
|
2369
|
May 15, 2020
|
Type I error in a specific design of 2-parallel group study
|
|
3
|
2782
|
March 11, 2020
|
RCT generalizability and interactions with treatment
|
|
8
|
3417
|
March 10, 2020
|
Presenting models of multiple (potentially recurring) outcomes
|
|
1
|
2416
|
March 6, 2020
|
Power for interaction effects
|
|
6
|
2189
|
February 24, 2020
|
Open label RCT: Placebo or Real effect?
|
|
5
|
2829
|
February 5, 2020
|
Handling withdrawn study subjects
|
|
6
|
2103
|
February 4, 2020
|
Marginal vs conditional (Mixed) models used in Joint model analysis. The SPRINT trial controversy
|
|
9
|
5453
|
December 2, 2019
|
2019 Nobel Prize in Economic Sciences is about limitations of RCT
|
|
15
|
3991
|
November 5, 2019
|
Adherence adjustment in randomized trials is possible, here's why
|
|
4
|
4251
|
July 9, 2019
|
RCT ceiling effects and high drop off rate
|
|
6
|
3113
|
October 14, 2019
|
How much patient variability is best for a clinical trial?
|
|
5
|
2752
|
September 22, 2019
|
Deviation in primary endpoint definition
|
|
12
|
2564
|
July 26, 2019
|
Advice/Opinion on (reviewing - ethics) an RCT analysis plan
|
|
1
|
1644
|
June 28, 2019
|
Sample size considerations for interaction covariate adjustment
|
|
11
|
3522
|
May 3, 2019
|
RCT of calcium supplementation to prevent pre-eclampsia. Huge conditional outcomes issue - what's the best analysis?
|
|
5
|
2563
|
March 8, 2019
|
DSMB Blinding: Yes or No?
|
|
12
|
4931
|
January 26, 2019
|
Interim Analysis & "Alpha Spending" in RCT's using Bayesian Analyses
|
|
15
|
5652
|
January 25, 2019
|
Inequality of Variances in an RCT
|
|
12
|
4321
|
December 27, 2018
|
Should we ignore covariate imbalance and stop presenting a stratified 'table one' for randomized trials?
|
|
41
|
23683
|
December 5, 2018
|